newsfilter
← Latest News
GlobeNewswire·

Mereo BioPharma Reports Third Quarter 2026 Financial Results

Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI) Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine